Trendy an­ti-ag­ing biotech Uni­ty adds $55M as it preps first hu­man tri­al to flush senes­cent cells

Uni­ty Biotech­nol­o­gy is fill­ing up its cash re­serves with an­oth­er ven­ture round be­fore it goes in­to its first an­ti-ag­ing hu­man stud­ies.

The Bay Area biotech bagged a $116 mil­lion celebri­ty round in 2016, with Jeff Be­zos and oth­ers join­ing the syn­di­cate for the Arch-seed­ed com­pa­ny, launched with Bob Nelsen’s help. That fol­lowed an $11 mil­lion seed round and a $35 mil­lion ex­ten­sion on the B. And now it’s set­tling for a rel­a­tive­ly mod­est $55 mil­lion for the C round, bring­ing the to­tal to 217 mil­lion so far for the pre­clin­i­cal com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.